{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-060299","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2026-05-13T20:33:41+00:00","discovered_at":"2026-05-13T20:34:18.442869+00:00","generated_at":"2026-05-13T20:34:43.940729+00:00","sec_items":["1.01","2.02","2.03","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Armata posts Q1 net loss of $115.3M ($3.16/diluted share); secures $25M Innoviva loan","bullets":["Net loss of $115.3M vs $6.5M in Q1 2025; loss includes non-cash items from warrant amendments.","Revenue of $0.8M (grant) up from $0.5M; R&D spend $6.1M vs $5.4M; cash $4.8M down from $8.7M.","Entered $25M secured term loan with Innoviva at 14% interest, maturing Jan 11, 2029.","AP-SA02 Phase 3 superiority study in S. aureus bacteremia expected to start H2 2026; FDA granted QIDP and Fast Track.","Appointed Daniel Gilmer to Board; ~36.7M shares outstanding as of May 8, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-060299","json":"https://secwatch.observer/filing/0001104659-26-060299.json","markdown":"https://secwatch.observer/filing/0001104659-26-060299.md","text":"https://secwatch.observer/filing/0001104659-26-060299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/armp-20260512x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T20:34:43.940729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"91c8d5c9491faf7f4c907f63ca1ebd07f0abde84","claim":"Armata Pharmaceuticals, Inc. incurred term loan of $25 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing January 11, 2029.","evidence_excerpt":"On May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of January 11, 2029.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm","confidence":1.0,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$25 million"},{"label":"Counterparty","value":"Innoviva Strategic Opportunities LLC"},{"label":"Rate","value":"14.0% per annum"},{"label":"Maturity","value":"January 11, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"8a550f554144a387f3dabb3a822e0dac097b6d73","claim":"Armata Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 13, 2026, the Company announced its financial results for the three months ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"0c34d8af1a38973398b530c3063b459e57c0b5f3","claim":"Armata Pharmaceuticals, Inc. entered into May 2026 Credit Agreement with Innoviva Strategic Opportunities LLC (Innoviva) valued at $25 million (effective 2026-05-12).","evidence_excerpt":"on May 12, 2026, it had entered into, as borrower, a credit and security agreement (the “May 2026 Credit Agreement”) with Innoviva Strategic Opportunities LLC (“Innoviva”), a wholly owned subsidiary of Innoviva, Inc., a principal shareholder of the Company. The May 2026 Credit Agreement provides for a secured term loan facility in an aggregate amount of $25 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465926060299/0001104659-26-060299-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Innoviva Strategic Opportunities LLC (Innoviva)"},{"label":"Value","value":"$25 million"},{"label":"Effective","value":"2026-05-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}